10X Genomics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.16. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| TXG | YINN | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $67.29 | $56.62 |
52-Week Low | $11.34 | $21.45 |
Enterprise Value | $8.08B | — |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
YINN, the Direxion Daily FTSE China Bull 3x ETF, is trading at $28.05, down 7.49% with a bearish technical signal. The leveraged ETF faces pressure from mixed Chinese economic policies and U.S.-China trade tensions. Recent news highlights China's AI investment plans and export controls, creating volatility. Technical indicators show strong bearish momentum with moving averages signaling sell pressure.
The outlook remains cautious due to YINN's leveraged structure amplifying risks amid geopolitical uncertainty. While China's tech sector shows IPO momentum, the fund's inherent decay and China's economic stabilization efforts present both opportunity and significant risk for investors seeking Chinese equity exposure.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →